Life-long Tele-monitoring of Patients With Type 2 Diabetes Mellitus in Central Greece

Overview

To evaluate whether patients with type 2 diabetes mellitus can be followed by simplified, centralized and large scale tele-monitoring of blood glucose levels and blood pressure, and whether this intervention produces health and economic benefits when introduced without major changes to the existing organization of a large tertiary care center.

Full Title of Study: “Renewing Health RCT for the Evaluation of Life-long Tele-monitoring of Patients With Diabetes Mellitus Type 2 in Central Greece”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2013

Detailed Description

The present study aims to examine the clinical and financial effects and the patients' perception and satisfaction of home telemedicine support system for diabetes management versus standard (usual) care. In the intervention group the patients will be provided with a blood glucose meter and a mobile phone and their data will be transferred via the mobile to the regional database and will be assessed by the allocated care team. Appropriate counseling on treatment and symptoms or problems related to diabetes will also be provided. Measurements of HbA1c will be taken to assess glycaemic control while the dietary and the exercise habits will be assessed by the use of questionnaires. In addition the patients' satisfaction from the use of the telemedicine service will be studied. A Cost-Effective Analysis and Cost Utility Analysis will be applied to evaluate the tele-health service compared with the usual care from the health and social perspective. The effect of the tele-health service in the organization structure of the outpatient hospital department will be evaluated with a qualitative study.

Interventions

  • Procedure: Telemonitoring of patients with diabetes type 2
    • Telemonitoring of the patients’s blood glucose level measurements using a the tele-glucose meter

Arms, Groups and Cohorts

  • No Intervention: Usual care
    • Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
  • Experimental: Telemonitoring of diabetes 2 patients
    • Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient’s home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.

Clinical Trial Outcome Measures

Primary Measures

  • Health related quality of life of the patients measured by the SF-36 version 2 questionnaire
    • Time Frame: 12 months minimum- at the entry point of the intervention and the end.
  • HbA1c levels
    • Time Frame: 12 months minimum – at the entry point and every 3 months.
    • Glycated hemoglobin (HbA1c) levels at the entry point and every 3 months (for a period of 12 months minimum)

Secondary Measures

  • Emotional functioning in diabetes assessed by the “Problem areas in diabetes questionnaire – PAID © 1999 Joslin Diabetes Center”
    • Time Frame: 12 months minimum- at the entry point of the intervention and the end.
  • Physical activity measured by the “International Physical Activity Questionnaire” (IPAQ)
    • Time Frame: 12 months minimum- at the entry point of the intervention and the end.
  • Nutrition habits assessed by validated questionnaire.
    • Time Frame: 12 months minimum- at the entry point of the intervention and the end.
  • Patients’ Acceptance-Satisfaction measured by the WSD Questionnaire
    • Time Frame: at 2nd and at 12th month
  • Economic Evaluation (Cost-Effective Analysis- Cost Utility Analysis)
    • Time Frame: 12 months minimum

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of type 2 Diabetes – HbA1c > 53 mmol/mol (7.0 % according to NGSP) – Capability to use the devices provided – Being cognitively able to participate – Capability of filling in questionnaires in german or greek language – Absence of severe comorbidity prevalent on diabetes with life expectancy < 12 months Exclusion Criteria:

  • Pregnancy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Regional Health Authority of Sterea & Thessaly
  • Collaborator
    • Ministry for Health and Social Solidarity, Greece
  • Provider of Information About this Clinical Study
    • Principal Investigator: Georgios Koukoulis, Associate Proffesor, Director of the Endocrinology and Metabolic Diseases Department, University Hospital of Larissa – Regional Health Authority of Sterea & Thessaly
  • Overall Official(s)
    • Georgios Koukoulis, MD, PhD, Principal Investigator, Endocrinology and Metabolic Diseases Department – Regional University Hospital of Larisa

References

Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K. Home telehealth for diabetes management: a systematic review and meta-analysis. Diabetes Obes Metab. 2009 Oct;11(10):913-30. doi: 10.1111/j.1463-1326.2009.01057.x. Epub 2009 Jun 16.

Klonoff DC. Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical? Diabetes Care. 2003 May;26(5):1626-8. doi: 10.2337/diacare.26.5.1626. No abstract available.

Jaana M, Pare G. Home telemonitoring of patients with diabetes: a systematic assessment of observed effects. J Eval Clin Pract. 2007 Apr;13(2):242-53. doi: 10.1111/j.1365-2753.2006.00686.x.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.